Skip to main content


Prescribe the topical that treats inflammatory lesions of rosacea. Help your patients get clearer faster and longer.1-3

Tube of cream.
Explore the Proposed Dual MOA of Ivermectin4-7
See the Superior Efficacy vs METROCREAM® (Metronidazole) Topical Cream, 0.75%8,9
Learn about the Highly Tolerable Safety Profile8,9
Time To Surface
Not an actual patient

aA phase 3, investigator-blinded, multicenter, randomized, parallel-group study comparing the efficacy and safety of SOOLANTRA (ivermectin) Cream, 1% once daily with METROCREAM (metronidazole) Topical Cream, 0.75% twice daily in 962 subjects aged 18 years and older with moderate to severe papulopustular rosacea (Investigator’s Global Assessment [IGA] score of 3 or 4) over a 16-week treatment period (Part A). A total of 757 successfully treated subjects, rated clear or almost clear (IGA score of 0 or 1), continued to the 36-week extension evaluating relapse after a treatment-free period (Part B).1,2

In Part B, subjects were followed every 4 weeks for up to 36 additional weeks (Weeks 16-52). If relapse (defined as IGA score of ≥2 [mild, moderate, or severe]) occurred, subjects were re-treated with the same treatment they had received during the initial 16-week study (Part A). Re-treatment was stopped when subject(s) achieved an IGA of ≤1 (clear or almost clear), with a maximum duration of re-treatment of 16 consecutive weeks to mimic the Part A treatment duration. Several re-treatment periods were permitted.2

See Important Safety Information